Relay Therapeutics Announces Formation of Oncology Advisory Board

Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, announced today the appointment of top oncology experts, scientists and leaders to its newly formed oncology advisory board.
“We are at a pivotal moment in the company’s growth and development as we become a clinical-stage company and we are delighted to have such an esteemed group of leaders to advise and support our team,” said Don Bergstrom, M.D., Ph.D., executive vice president and head of research and development at Relay Therapeutics. “The combined background and expertise of this advisory board will be invaluable as we develop our clinical strategy, continue to deepen our early-stage oncology portfolio, and realize our goal of bringing medicines to patients.”